Responsible for Global Partnering and
Business Development
CALGARY and SAN DIEGO, June 29,
2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC)
(OTCQX: ONCYF) (Oncolytics or the Company) today announced the
appointment of Andrew de Guttadauro
as President of its US subsidiary, Oncolytics Biotech (U.S.)
Inc. Mr. de Guttadauro, based in the Company's recently
opened satellite office in San Diego,
California, will primarily be responsible for simultaneously
pursuing both global and regional licensing, partnership and
commercialization opportunities for REOLYSIN®.
"Mr. de Guttadauro brings a breadth of industry knowledge,
experience and relationships to the Company and we are excited that
he has chosen to join us," said Dr. Matt
Coffey, President and CEO of Oncolytics Biotech. "Andrew
will lead our business development efforts, focusing on advancing
the development and eventual commercialization of REOLYSIN.
He represents an important expansion of our team as we seek to
capitalize on our compelling survival data in late stage breast
cancer patients and potentially to deliver new sources of
non-dilutive investment in the Company."
"I was excited to see a late stage immuno-oncology viral agent
like REOLYSIN, with such strong efficacy and safety data, maintain
its global rights," said Mr. de Guttadauro. "I am looking forward
to joining a mature and growing team as we advance partnership
discussions and prepare for our phase three registration study in
metastatic breast cancer."
Mr. de Guttadauro has more than 25 years of proven
biopharmaceutical commercialization and business development
experience. He was most recently a Principal at 1798 Consultants
Inc., a healthcare strategic advisory firm providing
commercialization consulting services across a number of areas
including market access strategy and tactics, healthcare policy,
and business development. Prior to that, he held executive
positions at biopharmaceutical companies including, Amgen, Biogen,
MedImmune and TAP Pharmaceuticals. Mr. de Guttadauro has
commercialization and business development experience covering
major developed and emerging markets globally.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, an immuno-oncology
viral-agent, as a potential treatment for a variety of tumor types.
The compound induces selective tumor lysis and promotes an inflamed
tumor phenotype through innate and adaptive immune responses to
treat a variety of cancers. Oncolytics' clinical development
program emphasizes three pillars: chemotherapy combinations to
trigger selective tumor lysis; immuno-therapy combinations to
produce adaptive immune responses; and immune modulator (IMiD)
combinations to facilitate innate immune responses.
Oncolytics is currently planning its first registration study in
breast cancer, as well as studies in combination with checkpoint
inhibitors and IMID/targeted therapies in solid and hematological
malignancies. For further information about Oncolytics,
please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements, including the
Company's belief as to the potential of REOLYSIN® as a
cancer therapeutic; the Company's expectations as to the success of
its research and development programs in 2017 and beyond, the
Company's planned operations, the value of the additional patents
and intellectual property; the Company's expectations related to
the applications of the patented technology; the Company's
expectations as to adequacy of its existing capital resources; the
design, timing, success of planned clinical trial programs; and
other statements related to anticipated developments in the
Company's business and technologies involve known and unknown risks
and uncertainties, which could cause the Company's actual results
to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN as a cancer
treatment, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should
consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to
update these forward-looking statements, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.